Comparison of protein- and polysaccharide-based nanoparticles for cancer therapy: synthesis, characterization, drug release, and interaction with a breast cancer cell line
Source abstract
Abstract
In this study, human serum albumin (HSA) was used as a protein-based material and poly (3-hydroxybutyrate) (PHB)-carboxymethyl chitosan (CMCh) as a polysaccharide-based material for the production of nanoparticles to be used as nanocarriers in cancer therapy. HSA and PHB-CMCh nanoparticles were prepared and characterized with a Zeta Sizer, Fourier transform infrared spectroscopy, scanning electron microscopy, and atomic force microscope. The effects of the pH value of the suspending medium and the amounts of crosslinker and polymer concentration on nanoparticle size and size distribution were investigated. The anticancer-agent etoposide was used as a model drug and encapsulated in nanoparticles to obtain drug release profiles. The entrapment efficiency of HSA nanoparticles was found to be greater than that of PHB-CMCh nanoparticles. To achieve "active" targeting of cancer cells, the nanoparticles were modified with concanavalin A. In the final step of the study, the interaction of nanoparticles with cancer cells was investigated in cytotoxicity and cellular uptake studies.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Protein Interaction Studies and Fluorescence Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Biology Department, Polatlı Art and Science Faculty, Gazi University, Ankara, Turkey;
Nanotechnology & Nanomedicine Division Hacettepe University, Ankara, Turkey;
Biology Department, Aksaray University, Aksaray, Turkey;
Chemistry Department, Biochemistry Division, Hacettepe University, Ankara, Turkey;
Bioengineering Department, Cyprus International University, Haspolat, Nicosia, Northern Cyprus, Turkey;
Hacettepe University Advanced Technologies Application and Research Center, HUNITEK, Ankara, Turkey
References (54)
Show source-provided references
1. Abraxane®. 2005. Abraxane Package Insert. Available from: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4235B2-01-01AbraxisBioscience-background.pdf.
2. 10.1016/j.carbpol.2005.08.00610.1016/j.carbpol.2005.08.006 ↗
3. Anitha A · J Biomater Sci Polym Ed · 2012 · 23 · 138110.1163/092050611X581534 ↗
4. 10.1016/j.carbpol.2009.05.02810.1016/j.carbpol.2009.05.028 ↗
5. 10.1016/S0065-3233(08)60640-310.1016/S0065-3233(08)60640-3 ↗
6. 10.1208/s12249-010-9489-610.1208/s12249-010-9489-6 ↗
7. 10.1080/0265204011006543110.1080/02652040110065431 ↗
8. 10.1016/j.msec.2012.11.02210.1016/j.msec.2012.11.022 ↗
9. Das S · Trends Biomater Artif Organs · 2005 · 18 · 203
10. 10.1016/j.msec.2015.10.01810.1016/j.msec.2015.10.018 ↗
11. Dustin LC · PLoS One · 2014 · 9 · e8732610.1371/journal.pone.0087326 ↗
12. 10.1166/jbn.2012.143110.1166/jbn.2012.1431 ↗
13. Ernest HR. · 1986
14. 10.1155/2009/57170210.1155/2009/571702 ↗
15. 10.5505/tjb.2012.2193110.5505/tjb.2012.21931 ↗
16. 10.1016/j.carbpol.2011.04.08310.1016/j.carbpol.2011.04.083 ↗
17. 10.1016/j.jconrel.2009.01.01310.1016/j.jconrel.2009.01.013 ↗
18. 10.1016/j.pmatsci.2010.03.00110.1016/j.pmatsci.2010.03.001 ↗
19. 10.1016/S0939-6411(00)00084-910.1016/S0939-6411(00)00084-9 ↗
20. 10.1177/088391150936073510.1177/0883911509360735 ↗
21. 10.1016/j.addr.2009.09.00410.1016/j.addr.2009.09.004 ↗
22. 10.1016/j.ejpb.2005.05.00910.1016/j.ejpb.2005.05.009 ↗
23. Kilicay E · Eur J Pharm Sci · 2011 · 44 · 31010.1016/j.ejps.2011.08.013 ↗
24. 10.1016/j.ijpharm.2006.03.04010.1016/j.ijpharm.2006.03.040 ↗
25. 10.3109/02652048.2010.50139510.3109/02652048.2010.501395 ↗
26. 10.1016/j.biomaterials.2003.08.06910.1016/j.biomaterials.2003.08.069 ↗
27. 10.1016/S0927-7757(00)00825-610.1016/S0927-7757(00)00825-6 ↗
28. 10.1016/j.ijpharm.2007.06.02810.1016/j.ijpharm.2007.06.028 ↗
29. 10.1016/0168-3659(95)00164-610.1016/0168-3659(95)00164-6 ↗
30. 10.3109/1061186930899608110.3109/10611869308996081 ↗
31. 10.1016/j.biomaterials.2005.12.02210.1016/j.biomaterials.2005.12.022 ↗
32. 10.1002/pola.2416510.1002/pola.24165 ↗
33. 10.1016/S0928-0987(00)00169-X10.1016/S0928-0987(00)00169-X ↗
34. Mo Y · Mol Vis · 2007 · 13 · 746
35. Mukerjee A · Anticancer Res · 2009 · 29 · 3867
36. 10.1016/0144-8617(88)90032-X10.1016/0144-8617(88)90032-X ↗
37. 10.1016/j.carbpol.2010.09.00910.1016/j.carbpol.2010.09.009 ↗
38. 10.1016/j.ijpharm.2008.08.02410.1016/j.ijpharm.2008.08.024 ↗
39. 10.1016/j.biocel.2006.06.01310.1016/j.biocel.2006.06.013 ↗
40. 10.1016/j.jcis.2012.08.06910.1016/j.jcis.2012.08.069 ↗
41. 10.1016/j.ijbiomac.2014.08.01210.1016/j.ijbiomac.2014.08.012 ↗
42. 10.1016/S0378-5173(97)00116-610.1016/S0378-5173(97)00116-6 ↗
43. 10.1007/b10011510.1007/b100115 ↗
44. 10.1021/bi00514a01410.1021/bi00514a014 ↗
45. 10.1172/JCI11583610.1172/JCI115836 ↗
46. 10.1517/17425247.5.2.15510.1517/17425247.5.2.155 ↗
47. 10.1016/j.ijpharm.2010.12.02310.1016/j.ijpharm.2010.12.023 ↗
48. 10.1016/S0142-9612(02)00440-410.1016/S0142-9612(02)00440-4 ↗
49. 10.1021/acs.jpcb.5b0014410.1021/acs.jpcb.5b00144 ↗
50. 10.1016/j.jconrel.2006.11.02810.1016/j.jconrel.2006.11.028 ↗
51. Yun Lu X · J Appl Polym Sci · 2010 · 116 · 294410.1002/app.31806 ↗
52. 10.1016/S0168-3659(00)00358-810.1016/S0168-3659(00)00358-8 ↗
53. 10.1007/s11051-014-2390-610.1007/s11051-014-2390-6 ↗
54. 10.1016/S0169-409X(01)00218-610.1016/S0169-409X(01)00218-6 ↗